drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR T cells)
drug_description
Autologous, gene-modified CAR T-cell therapy expressing two CARs targeting the EGFR 806 epitope and IL13Rα2; delivered intrathecally to induce T-cell activation, cytokine release, and cytotoxic killing of glioblastoma cells while aiming to reduce antigen escape through dual targeting.
nci_thesaurus_concept_id
C185590
nci_thesaurus_preferred_term
Autologous Anti-EGFR/Anti-IL13Ralpha2 CAR T-cells
nci_thesaurus_definition
A preparation of autologous T-lymphocytes engineered to co-express two chimeric antigen receptors (CARs) specific for epidermal growth factor receptor (EGFR) epitope 806 and interleukin-13 receptor alpha 2 (IL13Ra2), with potential immunostimulating and antineoplastic activities. After isolation, transduction, expansion and reintroduction into the patient, the autologous anti-EGFR/anti-IL13Ra2 CAR T-cells are directed to, bind to, and induce selective toxicity in EGFR deletion mutation variant III (EGFRvIII)-expressing and IL13Ra2-expressing tumor cells. EGFRvIII, an in-frame deletion of exons 2-7 in the EGFR gene, is overexpressed by a variety of cancer cell types but absent in normal, healthy cells. It plays a key role in tumor cell proliferation, tumor angiogenesis and resistance to both radio- and chemotherapy. IL13Ra2, a cancer-associated receptor, is overexpressed by a variety of tumor cell types including glioblastoma multiforme (GBM); it is associated with increased invasiveness of tumor cells. The binding of IL13Ra2 to EGFRvIII upregulates the tyrosine kinase activity of EGFRvIII and promotes tumor cell proliferation.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intrathecal
drug_mechanism_of_action
Autologous T cells genetically engineered (lentiviral) to co-express two chimeric antigen receptors targeting the EGFR 806 epitope and IL13Ra2. Engagement of either antigen on glioblastoma cells triggers CAR signaling to activate T cells, leading to cytokine release, clonal expansion, and perforin/granzyme-mediated cytotoxic killing. Dual targeting is intended to reduce antigen escape; administered intrathecally for CNS tumor access.
drug_name
CART-EGFR-IL13Ra2 Cells
nct_id_drug_ref
NCT05168423